Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Squamous Cell Carcinoma of Head and Neck 2Oropharyngeal Neoplasms 2Mouth Neoplasms 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Carcinoma 2Spinal Cord Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Recurrent Squamous Cell Lung Carcinoma 1Ovarian Neoplasms 1Nasopharyngeal Carcinoma 1Muscle Invasive Bladder Urothelial Carcinoma 1Lymphoid Interstitial Pneumonia 1Fallopian Tube Neoplasms 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 2Immunoglobulin G 2Disulfides 2Cetuximab 2(225)Ac-DOTA-c(RGDyK) 2pembrolizumab 1durvalumab 1atezolizumab 1acetyl-glycyl-asparagyl-glutaminyl-glutamyl-glutaminyl-valyl-seryl-prolyl-leucyl-threonyl-leucyl-leucyl-lysyl-lysyl-tryptophyl-cysteinyl-Alexa Fluoro 680 C2C2-maleimide conjugate 1X-Rays 1Thalidomide 1Standard of Care 1Specimen Handling 1Sentinel Lymph Node Biopsy 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiation 1Platinum 1Pilocarpine 1Photons 1Neck Dissection 1Fluorouracil 1Fluorodeoxyglucose F18 1Drug Therapy 1Docetaxel 1Dexamethasone 1Cyclophosphamide 1Cisplatin 1Chemotherapy, Adjuvant 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Mouth Neoplasms × Disulfides × Clear all
NCT05063552 2026-05-13

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03258554 2026-02-06

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡